Literature DB >> 9855118

Malignant neoplasm in kidney transplantation.

H Kishikawa1, Y Ichikawa, K Yazawa, T Hanafusa, T Fukunishi, C Ebisui, A Okuyama, S Nagano.   

Abstract

BACKGROUND: The kidney recipient is at a higher risk for cancer than is the general population, although the incidence of neoplasms in general is considered lower in Japan than in Western countries. The cause of this increased risk associated with either transplantation or geography has not yet been established.
METHOD: The incidences and sites of malignant neoplasms were analyzed in 285 kidney recipients, who had been followed up for 3007 patient-years. The relationship between immunosuppressive states, the numbers of CD4-positive T lymphocytes, and the presence of malignant neoplasms was studied retrospectively.
RESULTS: Eighteen malignant neoplasms were found in 17 of the 285 patients (6%). The malignancies developed in these patients an average of++ 1 26.5 months after transplantation. The incidence was only 3.9% at 10 years, increasing to 13.9% at 20 years. No difference in the time-course incidence was found between azathioprine-based and cyclosporin-based immunosuppressive regimens. The malignancies developed in the digestive organs in more than half of the patients, and were mainly in the liver, colon and rectum, and stomach, with a relatively low incidence of skin cancer and lymphoma. There was only one case of Epstein-Barr virus genome found in 5 specimens that were tested. Concerning the immunosuppressive state, CD4-positive T lymphocyte counts were not related directly with malignancies in our series.
CONCLUSION: The cumulative incidence of malignancy increased markedly in the second posttransplant decade. The site of cancers in kidney recipients mirrors that of general Japanese malignancies. Our results revealed neither the cause nor predictor for malignancies in kidney transplant patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855118     DOI: 10.1111/j.1442-2042.1998.tb00405.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis.

Authors:  Nobuyuki Miyake; Takafumi Ando; Kazuhiro Ishiguro; Osamu Maeda; Osamu Watanabe; Yutaka Hirayama; Keiko Maeda; Kazuhiro Morise; Masanobu Matsushita; Kazuhiro Furukawa; Kohei Funasaka; Masanao Nakamura; Ryoji Miyahara; Naoki Ohmiya; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  Treatment of advanced rectal cancer in a patient after combined pancreas-kidney transplantation.

Authors:  T T Zittel; C F R Mehl; U Reichmann; H D Becker; E C Jehle
Journal:  Langenbecks Arch Surg       Date:  2003-10-22       Impact factor: 3.445

3.  Primary enteric-type mucinous adenocarcinoma of the urethra in a patient with ulcerative colitis.

Authors:  Dimitrios Dimitroulis; Dimitrios Patsouras; Athanasios Katsargyris; Petros Charalampoudis; Ioannis Anastasiou; Gregory Kouraklis
Journal:  Int Surg       Date:  2014 Sep-Oct

Review 4.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.